文献速递血脂与心血管预防冠心病

活性归一化prime editing筛选实现LDLR变异分类

LDLR Variant Classification Through Activity-Normalized Prime Editing Screening.
PubMed 文献 · Circulation · 2026-09-01

研究建立首个活性归一化prime editing筛选流程,测量5184个LDLR编码变异对LDL-C摄取的影响,校正编辑效率差异;功能评分可区分致病与良性ClinVar变异并与UK Biobank的LDL-C水平一致,434个意义未明变异中322个可优先专家审查再分类,并发现LDLR A类重复5的功能获得性变异簇。

要点

  • 活性归一化prime editing可 scalable 分类LDLR变异,扩展可操作变异池。
  • 功能评分与ClinVar致病性及UK Biobank LDL-C水平一致。
  • 434个VUS/冲突/缺失变异中322个达再分类证据阈值。

核心结论

  • 活性归一化prime editing为LDLR变异分类提供可扩展框架,显著扩大有遗传诊断证据的变异比例并揭示治疗相关新生物学。

研究设计与样本

  • 开发首个活性归一化prime editing筛选流程,测量5184个LDLR编码变异对LDL-C摄取的影响。
  • 每条prime editing guide RNA配对基因型结果报告基因以校正编辑效率差异。
  • 统计框架联合分析每个氨基酸位置的所有错义变异以改进变异效应估计。

主要发现

  • 报告构建体的prime editing与内源性变异安装频率相关,验证活性归一化方法。
  • 所得评分捕捉连续功能效应谱,稳健区分致病与良性ClinVar变异,并与UK Biobank参与者LDL-C水平一致。
  • 434个当前为意义未明、冲突或ClinVar缺失的LDLR变异中,322个达再分类证据阈值可优先专家审查。
  • 筛选揭示LDLR A类重复5的功能获得性变异簇,至少部分通过增加载脂蛋白B相互作用增强LDL-C摄取。
  • prime editing独特检测cDNA筛选和致病性预测器遗漏的剪接影响编码变异。

关键数值与推荐

  • 功能证据强度校准至美国医学遗传学与基因组学学会/AMP变异解读框架,可整合临床变异分类工作流。
  • 结合功能、计算、人群和上下文证据,322/434个LDLR变异达再分类证据阈值。

临床怎么用

  • 可将功能证据整合至临床LDLR变异分类工作流,优先专家审查322个达阈值变异以扩展可操作分类。
  • 对意义未明LDLR变异患者,活性归一化prime editing评分可辅助判断致病性并指导降脂治疗与级联检测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Inherited variants in the LDL (low-density lipoprotein) receptor (LDLR) gene are the most common cause of familial hypercholesterolemia, significantly increasing coronary artery disease risk. Early identification of pathogenic LDLR variants enables prompt lipid-lowering therapy and cascade testing of at-risk relatives; however, most LDLR variants observed in the population have uncertain or absent clinical classifications, leaving many patients without actionable information. METHODS: We developed the first activity-normalized prime editing screening pipeline to measure the impact of 5184 LDLR coding variants on LDL-cholesterol (LDL-C) uptake. Each prime editing guide RNA is paired with a genotypic outcome reporter to correct for variable editing efficiency, overcoming a key limitation of previous pooled genome editing screens. A statistical framework further improves variant effect estimates by jointly analyzing all missense variants at each amino acid position. RESULTS: We show that prime editing of the reporter construct correlates with endogenous variant installation frequency, validating the activity normalization approach. The resulting scores capture a continuous spectrum of functional effects, robustly separate pathogenic versus benign ClinVar variants, and show concordance with LDL-C levels in UK Biobank participants. We calibrate functional evidence strengths to the American College of Medical Genetics and Genomics/AMP variant interpretation framework, enabling integration into a clinical variant classification workflow. By combining functional, computational, population, and contextual evidence, 322 of 434 LDLR variants currently classified as variants of uncertain significance, conflicting, or absent from ClinVar appear to meet evidence thresholds for reclassification and can be prioritized for expert review, substantially expanding the pool of actionable variant classifications. The screen also reveals a cluster of gain-of-function variants in LDLR class A repeat 5, at least some of which enhance LDL-C uptake through increased apolipoprotein B interaction, with implications for therapeutic genome editing. Last, prime editing uniquely detects splice-altering coding variants missed by cDNA-based screens and pathogenicity predictors, revealing an advantage of endogenous variant installation. CONCLUSIONS: Altogether, activity-normalized prime editing provides a scalable framework for LDLR variant classification that substantially expands the proportion of variants with evidence for genetic diagnosis and reveals novel biology with therapeutic relevance.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Zhou PJ, Velimirovic M, Yu T, et al. LDLR Variant Classification Through Activity-Normalized Prime Editing Screening. Circulation. 2026. PMID: 42677454. doi:10.1161/CIRCULATIONAHA.125.078585

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。